Incremental effect of clopidogrel on important outcomes in patients with cardiovascular disease: A meta-analysis of randomized trials

Thomas J. Helton, Anthony A. Bavry, Dharam J. Kumbhani, Sandeep Duggal, Henri Roukoz, Deepak L. Bhatt

Research output: Contribution to journalArticle

54 Citations (Scopus)

Abstract

Objectives: To quantify the impact of clopidogrel plus aspirin on the individual outcomes of death, myocardial infarction, or stroke in patients with established cardiovascular disease, or in patients with multiple risk factors for vascular disease. Background: Randomized trials have demonstrated a reduction in composite outcomes when clopidogrel is added to aspirin therapy in patients with coronary artery disease; however, the magnitude of benefit on individual outcomes is unknown. Methods: We conducted a meta-analysis on randomized, controlled trials that compared aspirin plus clopidogrel with aspirin plus placebo for the treatment of coronary artery disease. Results: This analysis included five randomized trials (CURE, CREDO, CLARITY, COMMIT, and CHARISMA) in 79 624 patients. The incidence of all-cause mortality was 6.3% in the aspirin plus clopidogrel group versus 6.7% in the aspirin group (odds ratio [OR] 0.94; 95% CI 0.89, 0.99; p = 0.026). The incidence of myocardial infarction was 2.7% and 3.3% (OR 0.82; 95% CI 0.75, 0.89; p < 0.0001), and stroke was 1.2% and 1.4% (OR 0.82; 95% CI 0.73, 0.93; p = 0.002). Similarly, the incidence of major bleeding was 1.6% and 1.3% (OR 1.26; 95% CI 1.11, 1.41; p < 0.0001), and fatal bleeding was 0.28% and 0.27% (OR 1.04; 95% CI 0.76, 1.43; p = 0.79). Conclusion: The addition of clopidogrel to aspirin results in a small reduction in all-cause mortality in patients with ST-elevation myocardial infarction and a modest reduction in myocardial infarction and stroke in patients with cardiovascular disease. The overall incidence of major bleeding however is increased, although there is no excess of fatal bleeds or hemorrhagic strokes.

Original languageEnglish (US)
Pages (from-to)289-297
Number of pages9
JournalAmerican Journal of Cardiovascular Drugs
Volume7
Issue number4
DOIs
StatePublished - 2007

Fingerprint

clopidogrel
Aspirin
Meta-Analysis
Cardiovascular Diseases
Odds Ratio
Stroke
Myocardial Infarction
Incidence
Hemorrhage
Coronary Artery Disease
Mortality
Vascular Diseases

ASJC Scopus subject areas

  • Pharmacology (medical)
  • Pharmacology

Cite this

Incremental effect of clopidogrel on important outcomes in patients with cardiovascular disease : A meta-analysis of randomized trials. / Helton, Thomas J.; Bavry, Anthony A.; Kumbhani, Dharam J.; Duggal, Sandeep; Roukoz, Henri; Bhatt, Deepak L.

In: American Journal of Cardiovascular Drugs, Vol. 7, No. 4, 2007, p. 289-297.

Research output: Contribution to journalArticle

Helton, Thomas J. ; Bavry, Anthony A. ; Kumbhani, Dharam J. ; Duggal, Sandeep ; Roukoz, Henri ; Bhatt, Deepak L. / Incremental effect of clopidogrel on important outcomes in patients with cardiovascular disease : A meta-analysis of randomized trials. In: American Journal of Cardiovascular Drugs. 2007 ; Vol. 7, No. 4. pp. 289-297.
@article{e5f92d66cec546b685563c47e87ef8e2,
title = "Incremental effect of clopidogrel on important outcomes in patients with cardiovascular disease: A meta-analysis of randomized trials",
abstract = "Objectives: To quantify the impact of clopidogrel plus aspirin on the individual outcomes of death, myocardial infarction, or stroke in patients with established cardiovascular disease, or in patients with multiple risk factors for vascular disease. Background: Randomized trials have demonstrated a reduction in composite outcomes when clopidogrel is added to aspirin therapy in patients with coronary artery disease; however, the magnitude of benefit on individual outcomes is unknown. Methods: We conducted a meta-analysis on randomized, controlled trials that compared aspirin plus clopidogrel with aspirin plus placebo for the treatment of coronary artery disease. Results: This analysis included five randomized trials (CURE, CREDO, CLARITY, COMMIT, and CHARISMA) in 79 624 patients. The incidence of all-cause mortality was 6.3{\%} in the aspirin plus clopidogrel group versus 6.7{\%} in the aspirin group (odds ratio [OR] 0.94; 95{\%} CI 0.89, 0.99; p = 0.026). The incidence of myocardial infarction was 2.7{\%} and 3.3{\%} (OR 0.82; 95{\%} CI 0.75, 0.89; p < 0.0001), and stroke was 1.2{\%} and 1.4{\%} (OR 0.82; 95{\%} CI 0.73, 0.93; p = 0.002). Similarly, the incidence of major bleeding was 1.6{\%} and 1.3{\%} (OR 1.26; 95{\%} CI 1.11, 1.41; p < 0.0001), and fatal bleeding was 0.28{\%} and 0.27{\%} (OR 1.04; 95{\%} CI 0.76, 1.43; p = 0.79). Conclusion: The addition of clopidogrel to aspirin results in a small reduction in all-cause mortality in patients with ST-elevation myocardial infarction and a modest reduction in myocardial infarction and stroke in patients with cardiovascular disease. The overall incidence of major bleeding however is increased, although there is no excess of fatal bleeds or hemorrhagic strokes.",
author = "Helton, {Thomas J.} and Bavry, {Anthony A.} and Kumbhani, {Dharam J.} and Sandeep Duggal and Henri Roukoz and Bhatt, {Deepak L.}",
year = "2007",
doi = "10.2165/00129784-200707040-00006",
language = "English (US)",
volume = "7",
pages = "289--297",
journal = "American Journal of Cardiovascular Drugs",
issn = "1175-3277",
publisher = "Adis International Ltd",
number = "4",

}

TY - JOUR

T1 - Incremental effect of clopidogrel on important outcomes in patients with cardiovascular disease

T2 - A meta-analysis of randomized trials

AU - Helton, Thomas J.

AU - Bavry, Anthony A.

AU - Kumbhani, Dharam J.

AU - Duggal, Sandeep

AU - Roukoz, Henri

AU - Bhatt, Deepak L.

PY - 2007

Y1 - 2007

N2 - Objectives: To quantify the impact of clopidogrel plus aspirin on the individual outcomes of death, myocardial infarction, or stroke in patients with established cardiovascular disease, or in patients with multiple risk factors for vascular disease. Background: Randomized trials have demonstrated a reduction in composite outcomes when clopidogrel is added to aspirin therapy in patients with coronary artery disease; however, the magnitude of benefit on individual outcomes is unknown. Methods: We conducted a meta-analysis on randomized, controlled trials that compared aspirin plus clopidogrel with aspirin plus placebo for the treatment of coronary artery disease. Results: This analysis included five randomized trials (CURE, CREDO, CLARITY, COMMIT, and CHARISMA) in 79 624 patients. The incidence of all-cause mortality was 6.3% in the aspirin plus clopidogrel group versus 6.7% in the aspirin group (odds ratio [OR] 0.94; 95% CI 0.89, 0.99; p = 0.026). The incidence of myocardial infarction was 2.7% and 3.3% (OR 0.82; 95% CI 0.75, 0.89; p < 0.0001), and stroke was 1.2% and 1.4% (OR 0.82; 95% CI 0.73, 0.93; p = 0.002). Similarly, the incidence of major bleeding was 1.6% and 1.3% (OR 1.26; 95% CI 1.11, 1.41; p < 0.0001), and fatal bleeding was 0.28% and 0.27% (OR 1.04; 95% CI 0.76, 1.43; p = 0.79). Conclusion: The addition of clopidogrel to aspirin results in a small reduction in all-cause mortality in patients with ST-elevation myocardial infarction and a modest reduction in myocardial infarction and stroke in patients with cardiovascular disease. The overall incidence of major bleeding however is increased, although there is no excess of fatal bleeds or hemorrhagic strokes.

AB - Objectives: To quantify the impact of clopidogrel plus aspirin on the individual outcomes of death, myocardial infarction, or stroke in patients with established cardiovascular disease, or in patients with multiple risk factors for vascular disease. Background: Randomized trials have demonstrated a reduction in composite outcomes when clopidogrel is added to aspirin therapy in patients with coronary artery disease; however, the magnitude of benefit on individual outcomes is unknown. Methods: We conducted a meta-analysis on randomized, controlled trials that compared aspirin plus clopidogrel with aspirin plus placebo for the treatment of coronary artery disease. Results: This analysis included five randomized trials (CURE, CREDO, CLARITY, COMMIT, and CHARISMA) in 79 624 patients. The incidence of all-cause mortality was 6.3% in the aspirin plus clopidogrel group versus 6.7% in the aspirin group (odds ratio [OR] 0.94; 95% CI 0.89, 0.99; p = 0.026). The incidence of myocardial infarction was 2.7% and 3.3% (OR 0.82; 95% CI 0.75, 0.89; p < 0.0001), and stroke was 1.2% and 1.4% (OR 0.82; 95% CI 0.73, 0.93; p = 0.002). Similarly, the incidence of major bleeding was 1.6% and 1.3% (OR 1.26; 95% CI 1.11, 1.41; p < 0.0001), and fatal bleeding was 0.28% and 0.27% (OR 1.04; 95% CI 0.76, 1.43; p = 0.79). Conclusion: The addition of clopidogrel to aspirin results in a small reduction in all-cause mortality in patients with ST-elevation myocardial infarction and a modest reduction in myocardial infarction and stroke in patients with cardiovascular disease. The overall incidence of major bleeding however is increased, although there is no excess of fatal bleeds or hemorrhagic strokes.

UR - http://www.scopus.com/inward/record.url?scp=34548103823&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=34548103823&partnerID=8YFLogxK

U2 - 10.2165/00129784-200707040-00006

DO - 10.2165/00129784-200707040-00006

M3 - Article

C2 - 17696569

AN - SCOPUS:34548103823

VL - 7

SP - 289

EP - 297

JO - American Journal of Cardiovascular Drugs

JF - American Journal of Cardiovascular Drugs

SN - 1175-3277

IS - 4

ER -